###begin article-title 0
###xml 46 54 <span type="species:ncbi:9606">Patients</span>
Increased Endothelin-1 Levels of BAL Fluid in Patients with Behcet's Disease
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Objective and background</italic>
###xml 421 428 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</italic>
###xml 709 716 709 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Results</italic>
###xml 948 959 948 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conclusions</italic>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
Objective and background. Pulmonary aneurysms and thrombosis constitute a significant cause of morbidity and mortality in Behcet's disease (BD). Various factors have been studied to explore the pathogenesis of vascular involvement in BD. As endothelin (ET) is known for its potent vasoconstrictor and proinflammatory properties, we supposed that it is involved during the inflammatory process of BD pulmonary vasculitis. Methods. To investigate the role of ET in BD, ET-1 concentrations were measured in bronchoalveolar lavage fluid (BALF) of 18 nonsmoking BD patients with pulmonary manifestations and 12 control subjects. Immunoreactivity of ET-1 was also evaluated in alveolar macrophages (AMs) cytoplasm. Results. ET-1 levels in BD-BALF were significantly higher than those of controls. ET-1 levels were correlated with the number of alveolar macrophages, but not with BAL-CD4/CD8 ratio. ET-1-immunoreactivity was found mainly in AM of BD-BAL. Conclusions. Increased ET-1 production from AM is associated with pulmonary BD manifestations.
###end p 2
###begin title 3
1. INTRODUCTION
###end title 3
###begin p 4
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
Behcet's disease (BD) is a multisystem inflammatory disorder characterized by recurrent oral ulcers, genital ulcers, and ocular inflammation, and frequently involves the joints, skin, gastrointestinal tract, central nervous system (CNS), and pulmonary manifestations [1-3]. BD is recognized as a multisystem vasculitis, which can affect all types of blood vessels [1]. During the course of BD, 25-37% of patients develop vascular complications [1-4].
###end p 4
###begin p 5
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 656 657 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
Recent evidence suggests that ET should be considered to be an inflammatory mediator [5, 6] and can stimulate macrophages and monocytes to release proinflammatory cytokines. Recent data also indicated that endothelial dysfunction (ED) is a constant feature of BD [7]. Etiology of ED in BD is probably multifactorial. Activation of both innate and Th1-type adaptive immune responses with enhanced expression of proinflammatory cytokines, adhesion molecules, free oxygen radicals [8], and high homocysteine levels [7] have all been suggested responsible for the activation of endothelial cells irrespective of overt vascular manifestations. Chambers et al. [9] observed an increase in FMD (brachial artery flow-mediated endothelium-dependent dilation) values following vitamin C administration in 12 patients, suggesting an important role of oxidative stress in endothelial dysfunction in BD. Inflammatory microenvironment in BD may cause reduced bioavailability of nitric oxide through proinflammatory cytokines as well as increased oxidized LDL cholesterol levels [10, 11].
###end p 5
###begin p 6
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 243 258 <span type="species:ncbi:10090">transgenic mice</span>
###xml 382 387 <span type="species:ncbi:9606">human</span>
ET has both mitogenic and proliferative actions on fibroblasts [12] in vitro and is produced by many types of lung cells such as endothelial cells [13], epithelial cells [14] and macrophages [6]. Interestingly, a recent study using human ET-1 transgenic mice has demonstrated that pulmonary ET-1 overexpression causes lung fibrosis [15]. ET-1 also induces fibronectin expression in human bronchial epithelium via an ETA receptor [16], suggesting a contribution of ET-1 as the intermediate pathogenesis of fibrosis because fibronectin is a potent chemotactic factor for fibroblasts [16].
###end p 6
###begin p 7
###xml 172 180 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
On this background, our study was planned to assess the contribution of bioactive ET to the pulmonary BD manifestations. For this purpose, ET concentration in BALF from BD patients was measured in BAL from active BD patients having pulmonary manifestation.
###end p 7
###begin title 8
2. MATERIALS AND METHODS
###end title 8
###begin title 9
###xml 5 13 <span type="species:ncbi:9606">Patients</span>
2.1. Patients
###end title 9
###begin p 10
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 316 323 316 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
###xml 578 581 <span type="species:ncbi:9606">men</span>
###xml 592 597 <span type="species:ncbi:9606">women</span>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
We studied 18 active BD patients (12 males and 6 females; nonsmoking patients; mean age: 49.8 years; range: 28-52 years). They were selected on the basis of the criteria defined by the International Study Group for diagnosis of Behcet's disease [17]. Clinical features of the patients with active stage are given in Table 1, which describe overall burden of the disease manifestations in BD patients. All active BD patients have pulmonary manifestations. Active BD patients were always treated with steroids and colchicine. The control subjects consisted of 12 nonsmokers (five men and seven women; mean age: 46.2 years; range: 32-48 years) undergoing routine investigations for suspected bronchial carcinoma and whose chest X-ray (CXR), bronchial examination, and pulmonary functions were normal. None of them had evidence of acute infection or chronic disease (e.g., other autoimmune or atopic disorders). Informed consent was obtained from all of the patients and control subjects. The design of the study was approved by our National Ethics Committee.
###end p 10
###begin title 11
2.2. Bronchoalveolar lavage
###end title 11
###begin p 12
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Bronchoscopy was performed according to standard guidelines, as described previously [18]. Thirty minutes prior to the procedure patients received 0.5 mg of atropine and 12.5 mg codeine intramuscularly. Local anaesthesia of the oropharynx was achieved by Novesine spray (Wander, Switzerland) until gag reflexes subsided. Bronchoscopy was performed using a Pentax bronchoscope through which 150 ml of normal prewarmed saline in aliquots of 20 ml were instilled into a subsegment of the right middle lobe. BAL fluid was then immediately aspirated by gentle hand suction into plastic tubes and kept at 4degreesC on ice.
###end p 12
###begin title 13
2.3. Processing of BAL cells
###end title 13
###begin p 14
BAL samples were filtered through a two-layer sterile gauze into sterile plastic vials (Falcon, Oxnard, CA, USA), centrifuged at 4degreesC and 500 grams for 10 minutes. The supernatant was removed and cells were washed twice in PBS. The total cell number was counted using a Neubauer hemocytometer (Brand, Wertheim, Germany). Differential cell counts were performed after Giemsa staining (Merck, Darmstadt, Germany) of cell smears with 1000 cells per slide counted.
###end p 14
###begin title 15
2.4. Analysis of T-lymphocyte subsets in BAL
###end title 15
###begin p 16
###xml 360 365 <span type="species:ncbi:10090">mouse</span>
BAL cells were incubated in the presence of saturating concentrations of fluorescein-conjugated MoAb against the surface markers CD3, CD4, and CD8 and isotype-matched control antibodies labelled with FITC, PE, and PE/CY5 (obtained from Dako, Hamburg, Germany) for 20 minutes at room temperature in the dark. Nonspecific fluorescence was detected by incubating mouse IgG of the same isotype, but with irrelevant antigen specificity. After two washes with PBS, the cells were analyzed by flow cytometry (FACScan; Becton Dickinson, Heidelberg, Germany).
###end p 16
###begin title 17
2.5. Extraction of ET and enzyme immunoassay
###end title 17
###begin p 18
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 444 446 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
Endothelin levels in BALF were assessed as described previously [19]. Briefly, the BALF sample (5 mL, thawed at 4degreesC) was loaded onto Sep-Pak C18 column (Millipore, Milford, MA, USA) that had been preactivated by methanol, and washed with 0.1% trifluoroacetic acid. Bound ET was eluted with methanol : water : trifluoroacetic acid (90 : 10 : 0.1) and evaporated by centrifugal freeze dryer. The resulting pellet was reconstituted with 500 muL of assay buffer, and then the concentration of extracted ET was measured using Endothelin Enzyme Immunoassay kit (R&D System Europe, Ltd., Abingdon Science Park, UK). The detection limit of the assay was 0.78 pg/mL.
###end p 18
###begin title 19
2.6. Immunocytochemistry
###end title 19
###begin p 20
###xml 575 576 563 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 577 578 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 574 578 562 566 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H<sub>2</sub>O<sub>2</sub></chem-struct>
###xml 128 134 <span type="species:ncbi:9986">rabbit</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 326 332 <span type="species:ncbi:9986">rabbit</span>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 371 382 <span type="species:ncbi:3704">horseradish</span>
###xml 403 407 <span type="species:ncbi:9925">goat</span>
###xml 413 419 <span type="species:ncbi:9986">rabbit</span>
BAL cells were centrifuged at 300 g for 10 minutes. The slides were air-dried and fixed in acetone. BAL cells were stained with rabbit mAb to human ET-1 (Biotrend Chemicals GmbH; Koln, Germany), using the unlabeled antibody method (indirect method). The slides were incubated for 1 hour at 37degreesC with a 1/200 dilution of rabbit mAb to human ET-1, and incubated with horseradish peroxidase, labeled goat anti-rabbit IgG for a further 1 hour at 37degreesC. Peroxidase was visualized by incubating slides in 3,3'-diaminobenzidine tetrahydrochloride and hydrogen peroxide (H2O2) for 2 minutes.
###end p 20
###begin title 21
2.7. Measurement of albumin
###end title 21
###begin p 22
The concentration of albumin in BALF was measured by ELISA kit (Exocell, Philadelphia, PA, USA). The assay followed a conventional ELISA format, using an antibody that recognizes antigen (albumin) in the test samples.
###end p 22
###begin title 23
2.8. Statistical analysis
###end title 23
###begin p 24
###xml 148 149 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 253 254 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 308 309 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Data are presented as mean +/- SE. Comparison of ET-1 levels in BALF between normal subjects and active BD patients was performed using the Student t test for paired samples. Correlations were tested by calculation of Pearson's correlation coefficient (r). Calculations were performed using the SPSS (10.0). P values of <.05 were considered statistically significant.
###end p 24
###begin title 25
3. RESULTS
###end title 25
###begin title 26
3.1. BAL differential cell count and CD4/CD8 ratio
###end title 26
###begin p 27
###xml 118 119 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 247 254 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 382 383 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 540 541 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
BALF recovery volumes were not different between active BD and healthy controls (52.7 +/- 9.6% versus 53.4 +/- 10.2%; P = .38). The BAL cell count tended to be higher in active BD than healthy controls, but did not reach statistical significance (Table 2). The percentage of lymphocytes was higher in active BD-BAL than in control subjects [(28.7 +/- 10.2%) versus (16.3 +/- 8.5%); P = .0002]. The percentage of 12 macrophages was not significantly different between active BD and healthy controls [(68.7 +/- 8.4%) versus (72.4 +/- 10.7%); P = .08]. No differences were observed in the percentages of neutrophils and eosinophils.
###end p 27
###begin p 28
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 149 150 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 299 300 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
The percentage of the CD4+ lymphocytes in BAL of patients with active BD (68.7% +/- 12.3%) was higher than that of normal controls (52.7% +/- 18.5%; P = .037). The CD4/CD8 ratio, in patients with active BD (2.26 +/- 0.8), was significantly increased when compared to healthy controls (1.16 +/- 0.3; P = .041).
###end p 28
###begin title 29
3.2. ET-1 levels in BALF
###end title 29
###begin p 30
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 160 168 160 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
Endothelin-1 levels in BALF from active BD were significantly higher in active BD than those from healthy controls (22.78 versus 7.23 ng/mg albumin, P < .004) (Figure 1).
###end p 30
###begin title 31
3.3. Correlation between ET-1 concentration and number of alveolar macrophages (AMs) in BALF
###end title 31
###begin p 32
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 207 215 207 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
There was a positive correlation (r = .56; P = .014) between the number of macrophages and ET-1 levels in BALF (Figure 2). No correlation (r = .08; P = .734) was found between ET-1 levels and CD4/CD8 ratio (Figure 3).
###end p 32
###begin title 33
3.4. Immunocytochemistry of ET-1
###end title 33
###begin p 34
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 418 425 416 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
The cytoplasm of BALF cells from patients with active BD was strongly stained with anti-ET-1, compared to healthy controls. The most stained cells in active BD were macro-phages (Figure 4). The percentage of AMs immunopositive for ET-1 was assessed in five fields and all of the macrophages were immunopositive for ET-1 in active BD BAL (84.77 +/- 12.49%), whereas <2% were positively stained in the healthy controls (Table 2). When macrophages were incubated for 24 hours without stimulation, culture media in active BD contained higher levels of ET-1 than for healthy controls.
###end p 34
###begin title 35
4. DISCUSSION
###end title 35
###begin p 36
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
Pulmonary manifestation in BD is one of the leading causes of death. Mean survival after the onset of hemoptysis was reported to be about 10 months [20, 21]. Recent reports of elevated serum concentrations of von Willebrand factor, plasminogen activator inhibitor-1, and thrombomodulin suggest that impaired vascular endothelial function contributes to vascular pathology in BD [22]. Endothelium-independent vasodilatation (EIVD) was found to be low in patients with BD [7].
###end p 36
###begin p 37
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
The source of ET-1 in the lung has been controversial. In the normal lung, ET-1 is known to be produced by several lung cells such as endothelial cells, epithelial cells, and AM [5]. Increased expression of immunoreactive ET-1 and ET-1 mRNA in pathological conditions including pulmonary manifestations has been demonstrated in AM and proliferating alveolar epithelial cells [5, 23].
###end p 37
###begin p 38
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
In this study, a significant correlation was observed between ET-1 concentrations and the number of AM. An increased presence of immunoreactive ET-1 in cytoplasm of AM from BD patients but not healthy controls was revealed by immunocytochemical assay. These data suggest that ET-1 could play an important role in inflammatory lung manifestations in these patients.
###end p 38
###begin p 39
###xml 174 179 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 185 190 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 274 276 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 278 280 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 281 283 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 317 322 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 329 334 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 507 509 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 576 581 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 600 605 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 611 615 587 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 640 645 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 652 656 621 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 720 725 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 731 735 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 745 750 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 801 803 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1318 1323 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1365 1367 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1369 1371 1320 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1395 1400 1346 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1473 1478 1420 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1516 1518 1459 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1551 1556 1494 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1640 1642 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1644 1646 1583 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 1263 1271 <span type="species:ncbi:9606">patients</span>
A variety of mediators, which could be involved in the intermediate pathogenesis of lung inflammation in BD patients, has been studied. Proinflammatory cytokines such as TNF-alpha, IFN-gamma, IL-1, IL-6, IL-8, and IL-18 are known to amplify the inflammatory response in BD [18, 24-26]. Macrophage inhibitory protein-1alpha (MIP-1alpha), a C-C chemokine, which stimulates the activation and migration of leukocytes, was found elevated in patients with BD, and correlates with IL-8, Rantes, and MCP-1 levels [27]. The expression of ET-1 mRNA was increased after incubation with alpha-(IL-8 and MGSA/Groalpha) and beta-chemokines (MCP-1, MIP-1alpha, MIP-1beta, and RANTES), and a mixture of 3 proinflammatory cytokines TNF-alpha, IL-1beta, and IFN-gamma was able to increase the mRNA expression of ET-1 [28]. These data provide several findings, the most significant of which is a stimulatory role for chemokines on the vascular endothelium. Our data support a local production of ET-1 within the pulmonary alveoli. In our study, most of the AMs expressed intracytoplasmic ET-1. This finding may be linked with the polarization of T-lymphocytes toward the Th1-type in BD as Th1 cytokines promote acceleration of macrophage function. Furthermore BAL fluid cells from patients with BD show increased mRNA expression of IFN-gamma and IL-18 compared with normal controls [18, 29]. In the same way, TNF-alpha increases the expression of ET-1 in bronchial epithelial cells, and TNF-alpha release is itself increased by ET-1 [30]. As a matter of fact, high TNF-alpha levels have been observed in BD sera, positively correlated with IL-18 production [31, 32].
###end p 39
###begin p 40
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 307 312 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 318 322 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 464 469 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 475 479 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 492 497 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 522 524 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
The interaction between ET and various cytokines may regulate/exacerbate the pathological events in pulmonary manifestations in BD. ET-1 has been launched as an important mediator in bronchi [33]. In animal studies, the increase in ET-1 mRNA level in lung tissue preceded the increase in mRNA levels of TNF-alpha, IL-1beta, and IL-8. Treatment of the animals with the ET receptor antagonist bosentan resulted in a substantial decrease in the concentrations of TNF-alpha, IL-1beta, interferon-gamma, and ET-1 in BAL fluid [33]. In BD, the interplay between ET-1 and proinflammatory mediators must be elucidated.
###end p 40
###begin p 41
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1759 1768 1759 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ischaemia</italic>
###xml 1770 1772 1770 1772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
###xml 879 887 <span type="species:ncbi:9606">patients</span>
###xml 1051 1059 <span type="species:ncbi:9606">patients</span>
###xml 2177 2185 <span type="species:ncbi:9606">patients</span>
Vascular endothelial dysfunction is a central event in the pathogenesis of a variety of human diseases, including adult respiratory distress syndrome, atherosclerosis, and diffuse systemic inflammatory disorders [34]. Endothelial injury seems to induce a dysfunction in nitric oxide (eNOS; iNOS) activity, resulting in a proinflammatory environment in association with tissue damage [34]. Recently, it has also been reported that reduced plasma nitric oxide (NO) levels in BD patients are implicated in the development of the endothelial abnormalities and thrombotic complications occurring in these patients [35]. An impairment of endothelium-dependent, flow-mediated dilatation has been described in BD suggesting a decreased endothelial NO activity, which may contribute to vascular lesions in BD. However, there have been conflicting reports about serum NO concentrations in patients with BD [36]. Recently, endothelial nitric oxide synthase gene Glu298Asp polymorphism was significantly associated with BD in a randomly selected group of Turkish patients [37]. The authors discussed the fact that with respect to the impaired NO production, the significant association of Glu298Asp polymorphism with BD may have a clinical implication as this polymorphism generates protein products with differing susceptibility to cleavage. They discussed the fact that this might have contributed to abnormally low NO generation. The combination of the paracrine effects of ET-1 along with release of NO is likely to have a relevant physiological role in the regulation of blood flow, as ET-1 and NO have opposite effects. ET-1 induces vasoconstriction and thrombosis contributing to ocular pathological manifestations and promoting retinal capillary nonperfusion and ischaemia [38]. Increased levels of VEGF and MCP-1 detected in BD thrombosis suggest the possible role of those angiogenic cytokines together with ET-1 in the pathogenesis of the disease. Moreover, ET-1 has mitogenic properties, with animal studies indicating a role in the proliferation of cultured airway smooth muscle cells and airway epithelial cells. The presence of endothelin-1 in increased concentration in BD patients' lungs suggests that further investigation of its role in pulmonary vessel remodeling is justified and potential interactions of endothelin-1 with other growth factors in BD remain to be clarified.
###end p 41
###begin title 42
ACKNOWLEDGMENTS
###end title 42
###begin p 43
This study was supported by the grant from "Ministere de l'Enseignement Superieur et de la Recherche of Tunisia; DGRST." Authors wish to thank Dr. Chahed Mohamed for the statistical analysis (Preventive Medicine Department).
###end p 43
###begin article-title 44
Behcet's syndrome
###end article-title 44
###begin article-title 45
Is Hughes-Stovin syndrome Behcet's disease?
###end article-title 45
###begin article-title 46
Pulmonary complications of Behcet's disease and Takayasu's arteritis
###end article-title 46
###begin article-title 47
A case of Behcet's disease with pulmonary arterial aneurysm and secondary amyloidosis
###end article-title 47
###begin article-title 48
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis
###end article-title 48
###begin article-title 49
Endothelin-1 secretion by alveolar macrophages in systemic sclerosis
###end article-title 49
###begin article-title 50
Endothelial functions in Behcet's disease
###end article-title 50
###begin article-title 51
Behcet's disease: an update on the pathogenesis
###end article-title 51
###begin article-title 52
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome
###end article-title 52
###begin article-title 53
###xml 61 66 <span type="species:ncbi:9606">human</span>
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
###end article-title 53
###begin article-title 54
###xml 262 270 <span type="species:ncbi:9606">patients</span>
The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behcet's disease
###end article-title 54
###begin article-title 55
Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts
###end article-title 55
###begin article-title 56
Effects of vasoactive and inflammatory mediators on endothelin-1 expression in pulmonary endothelial cells
###end article-title 56
###begin article-title 57
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical mapping of endothelin in the developing and adult mouse lung
###end article-title 57
###begin article-title 58
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice
###end article-title 58
###begin article-title 59
###xml 57 62 <span type="species:ncbi:9606">human</span>
Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells
###end article-title 59
###begin article-title 60
Criteria for diagnosis of Behcet's disease
###end article-title 60
###begin article-title 61
###xml 30 35 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
IL-18 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behcet's disease
###end article-title 61
###begin article-title 62
Blood and bronchoalveolar lavage endothelin-1 levels in nocturnal asthma
###end article-title 62
###begin article-title 63
Pulmonary involvement in Behcet disease
###end article-title 63
###begin article-title 64
Pulmonary artery aneurysms in Behcet syndrome
###end article-title 64
###begin article-title 65
Evidence for an endothelial cell dysfunction in association with Behcet's disease
###end article-title 65
###begin article-title 66
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis
###end article-title 66
###begin article-title 67
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Tc1/Tc2 ratio in the inflammatory process in patients with Behcet's disease
###end article-title 67
###begin article-title 68
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan
###end article-title 68
###begin article-title 69
###xml 77 85 <span type="species:ncbi:9606">patients</span>
T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behcet's disease
###end article-title 69
###begin article-title 70
###xml 54 59 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Enhanced production of macrophage inhibitory protein-1alpha in patients with Behcet's disease
###end article-title 70
###begin article-title 71
Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells
###end article-title 71
###begin article-title 72
Behcet's disease
###end article-title 72
###begin article-title 73
Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease
###end article-title 73
###begin article-title 74
###xml 48 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease
###end article-title 74
###begin article-title 75
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behcet's patients with venous thrombosis
###end article-title 75
###begin article-title 76
Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation
###end article-title 76
###begin article-title 77
Beauty and the beast. The nitric oxide paradox in systemic sclerosis
###end article-title 77
###begin article-title 78
Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcet's disease
###end article-title 78
###begin article-title 79
Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis
###end article-title 79
###begin article-title 80
Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behcet's disease
###end article-title 80
###begin article-title 81
Vascular endothelial growth factor in diabetes induced early retinal abnormalities
###end article-title 81
###begin title 82
Figures and Tables
###end title 82
###begin p 83
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 350 351 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Endothelin-1 concentration in BAL fluid from patients with active Behcet's disease (BD) and from healthy controls (HC). ET-1 levels were measured by enzyme immunoassay and were corrected by an albumin concentration in recovered lavage fluid. Values were expressed as median and the 25th-75th percentile. P values are also indicated (Student t test) (P = .004; t = -3.620; ddl: 11).
###end p 83
###begin p 84
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Correlation between endothelin-1 concentrations and the number of alveolar macrophages in BAL fluid from 18 active BD patients with pulmonary manifestations. (P = .014; r = .56).
###end p 84
###begin p 85
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Correlation between endothelin-1 concentrations and CD4/CD8 ratio of alveolar macrophages in BAL fluid from 18 active BD patients with pulmonary manifestations. (P = .734; r = .08).
###end p 85
###begin p 86
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 128 134 <span type="species:ncbi:9986">rabbit</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
Immunocytochemical detection of endothelin-1 in BAL cells from control subjects (a), and from patients with active BD (b) using rabbit mAb to human endothelin-1. Cytoplasm of BALF cells from patients with active BD was strongly stained. The immunostaining also demonstrated that most of the immunopositive cells in the BD BALF were macrophages.
###end p 86
###begin p 87
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">Patients</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
Clinical features of patients with Behcet's disease (BD) with pulmonary manifestations. Overall burden of the disease manifestations in BD patients is described. Patients received colchicine, steroids/cyclosporine. Five patients with oral ulcer, genital ulcer, uveitis, and vasculo-symptoms were newly diagnosed. All patients had pulmonary aneurysms.
###end p 87
###begin p 88
###xml 21 29 <span type="species:ncbi:9606">patients</span>
BAL fluid results in patients with active Behcet's disease and control subjects. Data are expressed as mean +/- SEM.
###end p 88
###begin p 89
###xml 0 8 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8224;)</sup>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
(dagger)Data are from 18 BALs performed in 18 active BD patients and 12 BALs performed in 12 control subjects.
###end p 89
###begin p 90
###xml 0 15 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8225;)</sup>
###xml 28 29 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
(double dagger)Mann-Whitney U test.
###end p 90

